R submission Pilots to FDA - By the R consortium R submission Working Group

Presenter: Ning Leng, People and Product Lead, Product Development Data Sciences, Roche-Genentech (we are hiring!)



R Submission Working Group:

A cross industry collaboration to improve open-source language usage in the regulatory setting

































Pilot 1 Submission to FDA:

A successful open pilot that showcased using R in FDA submission

Key evaluation aspects:

- For Submitter
 - Submission of a proprietary R package ('pilot1wrappers', in txt format)
 - Preparation of R-based submission materials (ADRG, etc.)
- For FDA staff
 - Reproduce analysis results by reconstructing submitted proprietary package ('pilot1wrappers') / retrieving open source packages
 - Provide feedbacks and/or review comments

Data and analysis scope:

- Data from CDISC pilot 1 publicly available, simulated data
 - Data generation script out of the scope of this pilot
- 4 TLFs 3 tables, 1 figure
 - This pilot will provide R scripts for TLF generation and a proprietary R package which contains analysis wrappers



NDA/BLA #:	BLA 111111 (R pilot submission) R Consortium's R Submission Working Group	
Applicant:		
Statistical Analyst	Hye Soo Cho, AIS	Hye Soo Cho -S Depthy signating type law Cha 4 Depthy signating type law Cha 4 Depthy Soo Cho 4 Depthy Soo C
Supervisor	Maria Matilde Kam, AIS	Maria Matilde S. Kam -5 Standard Comments, and Policy and Name Angels. Standard Comments, and Policy and Name Angels. Standard Comments and Angels. Sta
Date(s):	March 10, 2022	
Objectives of the submission	To test and support R-based clinical trial application submission	
Location of datasets and programs	\\cdsesub3\evsprod\BLA111111\0002	
Reviewed tables and figures	Table 14-2.01, Table 14-3.01, Table 14-3.02, Figure 14-1	

Summar

- An FDA analyst was able to complete the following tasks:
- Receive electronic submission package in eCTD format
- o Reconstruct and load the submitted proprietary R package
- Install and load open-source packages used in this submission
- Reproduce the analysis results
- Share potential improvements to the submission deliverable and processes via a written communication
- FDA agrees that the initial phase of the R Pilot submission has been completed.
- For future reference, FDA suggest calculating 95% confidence intervals in a consistent manner.

The Submission pilot 1 execution team Ning Leng, Heng Wang (Roche) Mike Stakehouse, Eli Miller (Atorus)

Yilong Zhang, Peikun Wu (Merck)

Key Links

- Webpage: https://rconsortium.github.io/submissions-wg/
- https://github.com/RConsortium/submissions-pilot1-to-fda
 - Final submission folder for Pilot 1 following eCTD required folder structure

All materials are open to the public

Anyone is welcome to join the working groups! (info@r-consortium.org)

Next Steps

- Pilot 2: shiny based pilot submission to FDA
- Pilot 1 extensions: pilots to additional agencies (Japan-PMDA, HTAs)